A randomized, double-blind, parallel controlled trial for San-Wei Qing-Zhi decoction in the treatment of hyperlipidemia

ingjin County Hospital, Xingtai City, Hebei province0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•(1) low-density lipoprotein (ldl-c) >=3.4mmol/L;
•(2) meet the diagnostic criteria of TCM syndrome of mutual phlegm and blood stasis syndrome (score >=6 points);
•(3) outpatient or inpatient male and female patients aged 18-70 years;
•(4) sign the informed consent.

•(1) pregnant or lactating women and allergic conditions (allergic to 2 or more foods, drugs or other substances such as paint and pollen);
•(2) patients with acute myocardial infarction, cerebrovascular accident, severe trauma or major surgery within half a year;
•(3) secondary hyperlipidemia (by systemic diseases such as diabetes, nephrotic syndrome, hypothyroidism, kidney failure, liver disease, systemic lupus erythematosus (sle), glycogen storage disease, multiple myeloma, fat atrophy, acute porphyrin disease, such as polycystic ovary syndrome, or by certain drugs, such as diuretics, glucocorticoid, beta blockers such as cause dyslipidemia);
•(4) patients with sugar metabolic abnormalities (I diabetes, II of poorly controlled diabetes, fasting plasma glucose or greater tendency for 10.0/L, HbA1c >8.0%);
•(5) patients with severe primary diseases including liver, kidney and hematopoietic system;
•(6) mental patients;
•(7) familial hypercholesterolemia;
•(8) those taking part in other drug tests.

发起方

ingjin County Hospital, Xingtai City, Hebei province